ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS

被引：0
|
作者：
Coates, Laura C. [1 ]
Merola, Joseph F. [2 ]
Fitzgerald, Oliver [3 ,4 ]
Kavanaugh, Arthur [5 ]
Gottlieb, Alice B. [6 ]
Tillett, William [7 ]
Bauer, Lars [8 ]
Hoepken, Bengt [8 ]
Nurminen, Tommi [8 ]
Mease, Philip J. [9 ,10 ]
Helliwell, Philip [11 ]
van der Heijde, Desiree [12 ]
机构：
[1] Nuffield Orthopaed Ctr, Oxford, England
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] St Vincents Univ Hosp, Dublin, Ireland
[4] Univ Coll Dublin, Conway Inst Biomol Res, Dublin, Ireland
[5] UC San Diego Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA USA
[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[7] Royal Natl Hosp Rheumat Dis, Bath, Avon, England
[8] UCB Pharma, Monheim, Germany
[9] Swedish Med Ctr, Seattle, WA USA
[10] Univ Washington, Seattle, WA 98195 USA
[11] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[12] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.765
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0742
引用
收藏
页码：1836 / 1837
页数：2
相关论文
共 50 条
  • [1] Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
    Coates, Laura
    Merola, Joseph
    Kavanaugh, Arthur
    Mease, Philip
    Davies, Owen
    Irvin-Sellers, Oscar
    Nurminen, Tommi
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
    Coates, L. C.
    Merola, J. F.
    Kavanaugh, A.
    Mease, P. J.
    Davies, O.
    Irvin-Sellers, O.
    Nurminen, T.
    Van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 754 - 755
  • [3] Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
    Queiro, Ruben
    Canete, Juan D.
    Montilla, Carlos
    Angel Abad, Miguel
    Montoro, Maria
    Gomez, Susana
    Cabez, Ana
    Torre Alonso, J. C.
    Roman-Ivorra, J. A.
    Sanz, J.
    Salvatierra, J.
    Calvo-Alen, J.
    Sellas, A.
    Rodriguez, F. J.
    Bermudez, A.
    Romero, M.
    Riesco, M.
    Cobeta, J. C.
    Medina, F.
    Aragon, A.
    Garcia, M. L.
    Urruticoechea, A.
    Gonzalez, C. M.
    Judez, E.
    Gonzalez, B.
    Fernandez, P.
    Pantoja, L.
    Morla, R.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 710 - 715
  • [4] CERTOLIZUMAB PEGOL PROVIDES SUSTAINED REMISSION AND MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS OVER 4 YEARS' TREATMENT
    van der Heijde, D.
    Deodhar, A.
    FitzGerald, O.
    Fleischmann, R.
    Gladman, D.
    Gottlieb, A. B.
    Coates, L. C.
    Hoepken, B.
    Bauer, L.
    Peterson, L.
    Khraishi, M.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1027 - 1027
  • [5] Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) that Reflects High, Moderate and Low Disease Activity as well as Minimal Disease Activity (MDA) in PsA
    Got, Matthew
    Li, Suzanne
    Perruccio, Anthony
    Gladman, Dafna
    Chandran, Vinod
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1220 - 1221
  • [6] COMPARISON OF PSORIATIC ARTHRITIS THERAPEUTIC TARGETS - PSA-MDA AND DAPSA REMISSION/LOW DISEASE ACTIVITY IN PATIENTS TREATED IN THE INSTITUTE OF RHEUMATOLOGY PRAGUE
    Stolfa, J.
    Sedova, L.
    Mares, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1587 - 1588
  • [7] DEFINING THE THERAPEUTIC TARGET IN PSORIATIC ARTHRITIS: ASSOCIATION BETWEEN MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA)
    Coronel Ale, A. L.
    Cerda, O. L.
    Fornaro, M. N.
    Isnardi, C. A.
    Schneeberger, E. E.
    Citera, G.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S117 - S118
  • [8] FURTHER ANALYSIS OF PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE (PASDAS) AND COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX (CPDAI) USING DATA FROM A PLACEBO-CONTROLLED TRIAL OF CERTOLIZUMAB PEGOL IN PSORIATIC ARTHRITIS
    Helliwell, P.
    Mease, P. J.
    Nurminen, T.
    FitzGerald, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 740 - 740
  • [9] Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
    Paul, Stephane
    Marotte, Hubert
    Kavanaugh, Arthur
    Goupille, Philippe
    Kvien, Tore K.
    de Longueville, Marc
    Mulleman, Denis
    Sandborn, William J.
    Vande Casteele, Niels
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (04): : 743 - 751
  • [10] The Assessment of Disease Activity in Psoriatic Arthritis: MDA, VLDA, DAPSA, or Something Else?
    Lubrano, Ennio
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 663 - 664
12345